Navigation Links
ViroPharma to Participate in Two May Healthcare Investor Conferences
Date:4/30/2010

EXTON, Pa., April 30 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that William Roberts, vice president, corporate communications of ViroPharma, will present at the Deutsche Bank 35th Annual Healthcare Conference at 1:30 P.M. ET on Tuesday, May 4, 2010.  The conference is being held at the InterContinental Hotel in Boston.

Vincent Milano, president and chief executive officer, of ViroPharma, will present at the Bank of America/Merrill Lynch 2010 Healthcare Conference at 10:00 A.M. ET on Tuesday, May 11, 2010.  The conference is being held at the Grand Hyatt in New York City.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze™ (C1 esterase inhibitor [human]) for routi
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ViroPharma to Present at Two Upcoming Healthcare Conferences
2. ViroPharma Provides 2008 Outlook
3. ViroPharma to Present at the BIO CEO & Investor Conference
4. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
5. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
6. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
7. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
8. ViroPharma to Present at Two Upcoming Healthcare Conferences
9. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
10. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
11. ViroPharma To Acquire Lev Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... light, rather than electricity, to move data would ... is a growing concern as chips, transistor counts ... optical circuits light emitters, modulators, and detectors ... promising light source for optical chips is molybdenum ... deposited as a single, atom-thick layer. Other experimental ...
(Date:9/19/2014)... 19, 2014  An entire month is dedicated to ... – Charcot-Marie-Tooth disease (CMT) – a debilitating neuromuscular disease ... muscle atrophy, weakness, and foot and hand deformities. CMT ... worldwide. CMT is a progressive disease, and over time ... mobility devices such as leg braces, wheelchairs and scooters ...
(Date:9/19/2014)... 19, 2014  Nektar Therapeutics (NASDAQ: ... characterizing the analgesic profiles of a series of ... agonist molecules. The preclinical research candidates were created ... The analgesic properties of kappa receptor ... 1,2 Kappa opioid receptors are expressed in ...
(Date:9/19/2014)... SPRINGS, Florida , September 19, 2014 ... companies release latest developments, patents and results of studies ... GNSZ), Eli Lilly and Company (NYSE: LLY ... Celgene Corporation (NASDAQ: CELG ) and Arena ... GNSZ), a leader in developing prodrug therapeutics for the ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7
... SAN DIEGO, Oct. 28 Neurocrine Biosciences,(Nasdaq: NBIX ) announces the ... 2008 Financial Results, When: October 28, 2008 @ ... http://www.videonewswire.com/event.asp?id=52783 , How: Live over the Internet ... above., Contact: Claudia ...
... U.S. Phase II Study,of Nitazoxanide in Treatment-Naive Patients ... Oct. 28 Romark Laboratories, a privately,held biopharmaceutical ... at the upcoming 59th Annual Meeting of the ... also known as The,Liver Meeting(R), and the 50th ...
... Ziplex automated gene-expression system at the ... ... Molecular, a pioneer in,the development of cost-effective, easy-to-use gene-expression analysis,systems, ... L. Wittliff, a professor in the Department of,Biochemistry and Molecular ...
Cached Biology Technology:Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco 2James L. Wittliff, Ph.D., FACB, to Present 'Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System' at the Association for Molecular Pathology Conference, October 30 2James L. Wittliff, Ph.D., FACB, to Present 'Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System' at the Association for Molecular Pathology Conference, October 30 3
(Date:9/18/2014)... in DNA, tiny strands of nucleic acid that contain ... this genetic data, our DNA is copied into RNA ... perform tasks in our cells. , Several years ... Unlike all other known RNAs, this molecule is circular, ... abundant, little has been known about how they are ...
(Date:9/18/2014)... ALEXANDRIA, Va.Sept. 18, 2014Many Americans across racial and ... the greatest impact on their day-to-day life, more ... memory, hearing and speech (57% of African-Americans, 49% ... of Hispanics). When asked which disease or ailment ... blindness ranked first among African-Americans followed by AIDS/HIV. ...
(Date:9/18/2014)... have devastated algal forests in the eastern Mediterranean Sea ... if their distribution continues to expand as the climate ... international team of researchers led by Dr Adriana Vergs ... Mediterranean Institute for Advanced Studies in Spain, is published ... the team surveyed more than 1000 kilometres of coastline ...
Breaking Biology News(10 mins):Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3Tropical fish a threat to Mediterranean Sea ecosystems 2
... of life -- kids get sick and have fevers. ... but in some small children they spark convulsions called ... very upsetting to parents," said Robert L. Macdonald, M.D., ... something of an enigma, he said. The epilepsy research ...
... development of drug-resistant HIV when patients take as few as ... only when patients take most of their pills. These differences ... "fitness" of the drug-resistant HIV, say AIDS researchers in a ... MPH, an AIDS specialist at the University of California, San ...
... Vaccine and Infectious Disease Organization (VIDO) have developed a vaccine ... against a disease for which no vaccines are yet available. ... this vaccination technique may be effective against HCV. The study ... , The team, funded by the Canadian Institutes of Health ...
Cached Biology News:Molecular mechanism may explain how fevers spark seizures 2Molecular mechanism may explain how fevers spark seizures 3Viral 'fitness' explains different resistance patterns to aids drugs 2U of S researchers develop new vaccine candidate against hepatitis C 2
... EVO96R and Freedom EVO384R are fast multi-channel ... in three different sizes, with a multi-channel ... deliver significant time saving, with true parallel ... setup of your assays with the Freedom ...
... are fast multi-channel pipetting platforms consisting of ... with a multi-channel head and a robotic ... with true parallel processing of sample plates ... with the Freedom EVOware program. ...
Prepared by multi-temperature ethanol fractionation with extensive charcoal treatment and dialysis.• Assay: ≥ 95 % (HPCE)• pH ~5.2 (10 mg/mL in 0.15 M NaCl)...
... Linkage: This CLS number is a ... match Cornings product number. If showing ... the old Sigma-Aldrich number (Z71,405-4) or ... Dim: diam. 60 mm volume ...
Biology Products: